Cibus, Inc.
NASDAQ:CBUSBiotechnology
+$0.04 today
- Market cap
- $94.01M
- Beta
- 1.65
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.16
Volume 0.19M
Average 0.51M
Returns on capital
Cibus, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-582.2%
avg -160.2%
ROIC
-23.2%
avg -59.6%
ROA
-41.7%
avg -53.4%
Analysis
ROIC is currently the strongest return metric at -23.2% versus its period average of -59.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Rory Balfour Riggs | Co-Founder & Director | USD 1.09M | 73 | — | — |
Peter Beetham | Co-Founder, President & COO | USD 630.58K | 63 | 390.00K | 0.86% |
Gregory F. Gocal | Co-Founder, Chief Scientific Officer & Executive Vice President | USD 455.02K | 57 | — | — |
Jason Stokes | Chief Administrative Officer, General Counsel & Corporate Secretary | USD 439.71K | 55 | 164.35K | 0.36% |
Cornelis Broos | Chief Financial Officer | USD 238.98K | 54 | — | — |
Craig Wichner | Chief Executive Officer | USD 9.29K | 56 | 894.31K | 1.97% |
Rosa Cheuk Kim | Senior Vice President of Legal | — | — | — | — |
Noel Sauer | Senior Vice President of Research | — | 59 | 138.04K | 0.30% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +185.1% | +147.3% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +185.1% over three years. Forward estimates point to Revenue at +147.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Cibus, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CBUS's management, answered from reported figures.
Who manages CBUS?
Cibus, Inc. (CBUS) lists 8 active executives. The top listed executive is Gregory F. Gocal, Co-Founder, Chief Scientific Officer & Executive Vice President.
Are CBUS insiders buying or selling?
Recent insider activity shows net buying of $29.84M.
Continue the stock analysis
Jump to another research area for this company.